Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PALI Stock Summary
Top 10 Correlated ETFs
PALI
In the News
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at DDW 2024 being held in Washington, D.C., May 18-21, 2024.
Why Is Palisade Bio (PALI) Stock Up 100% Today?
Biopharmaceutical company Palisade Bio (NASDAQ: PALI ) is seeing its market value skyrocket off multiple encouraging catalysts today. While PALI stock still remains an extremely risky proposition, investors are being buoyed by some key developments.
Why Is Palisade Bio (PALI) Stock Down 46% Today?
Palisade Bio (NASDAQ: PALI ) stock is falling on Thursday after the clinical-stage biopharmaceutical company announced a share offering. Palisade Bio is selling 2,339,398 shares of PALI stock through a registered direct offering.
Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up
Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies.
Palisade Bio's stock more than doubles on news of licensing deal with Giiant Pharma for IBD therapies
Palisade Bio Inc.'s stock PALI more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant Pharma Inc. Carlsbad, Calif.-based Palisade said the license gives it exclusive worldwide rights to develop, make and commercialize Giiant's proprietary targeted prodrug platform which specializes in therapies for the IBS market.
Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Live webcast fireside chat on Thursday, June 22 nd at 11:30 AM ET
Palisade Bio, Inc. (PALI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Palisade Bio, Inc. (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Palisade (PALI) Enrolls First Patient in LB1148 Study in China
Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.
Why Is Palisade Bio (PALI) Stock Up 36% Today?
Palisade Bio (NASDAQ: PALI ) stock is on the rise Friday after the biopharmaceutical company got an upgrade from an analyst. Maxim Group is behind today's upgrade for PALI stock.
What Makes Palisade Bio, Inc. (PALI) a New Buy Stock
Palisade Bio, Inc. (PALI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PALI Financial details
PALI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 17.15 | 2.1 | 0.24 | 0 | 0 | |
Net income per share | -324.91 | -1.14K | -190.5 | -145.87 | -14.54 | |
Operating cash flow per share | -507.52 | -990.57 | -85.93 | -79.02 | -15.18 | |
Free cash flow per share | -507.63 | -990.57 | -86.04 | -79.02 | -15.19 | |
Cash per share | 381.81 | 698.3 | 13.14 | 56.14 | 14.07 | |
Book value per share | 399.13 | 699.82 | -299.21 | 39.39 | 14.18 | |
Tangible book value per share | 348.75 | 608.49 | -299.21 | 39.39 | 14.18 | |
Share holders equity per share | 399.13 | 699.82 | -299.21 | 39.39 | 14.18 | |
Interest debt per share | 0.51 | 25.92 | 29.84 | 13.89 | 0.47 | |
Market cap | 28.19M | 2.18M | 14.65M | 12.15M | 4.58M | |
Enterprise value | 22.4M | -2.76M | 15.36M | 1.86M | -7.4M | |
P/E ratio | -5.72 | -0.26 | -1.39 | -0.45 | -0.36 | |
Price to sales ratio | 108.43 | 141.32 | 1.08K | 0 | 0 | |
POCF ratio | -3.66 | -0.3 | -3.07 | -0.82 | -0.34 | |
PFCF ratio | -3.66 | -0.3 | -3.07 | -0.82 | -0.34 | |
P/B Ratio | 4.66 | 0.42 | -0.88 | 1.65 | 0.37 | |
PTB ratio | 4.66 | 0.42 | -0.88 | 1.65 | 0.37 | |
EV to sales | 86.17 | -179.2 | 1.14K | 0 | 0 | |
Enterprise value over EBITDA | -4.74 | 0.33 | -1.52 | -0.04 | 0.49 | |
EV to operating cash flow | -2.91 | 0.38 | -3.22 | -0.13 | 0.55 | |
EV to free cash flow | -2.91 | 0.38 | -3.22 | -0.13 | 0.55 | |
Earnings yield | -0.17 | -3.84 | -0.72 | -2.24 | -2.8 | |
Free cash flow yield | -0.27 | -3.34 | -0.33 | -1.22 | -2.92 | |
Debt to equity | 0 | 0.04 | -0.09 | 0.03 | 0.03 | |
Debt to assets | 0 | 0.03 | 0.47 | 0.02 | 0.03 | |
Net debt to EBITDA | 1.22 | 0.58 | -0.07 | 0.23 | 0.79 | |
Current ratio | 6.19 | 4.61 | 0.11 | 4.96 | 4.89 | |
Interest coverage | -1.07K | -967.68 | -39.56 | -17.45 | -1.21K | |
Income quality | 1.56 | 0.87 | 0.46 | 0.56 | 0.94 | |
Dividend Yield | 0 | 0 | 0 | 0.01 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 17.54 | 472.39 | 458.43 | 0 | 0 | |
Research and developement to revenue | 15.23 | 263.83 | 229.22 | 0 | 0 | |
Intangibles to total assets | 0.1 | 0.1 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.01 | 0 | -0.44 | 0 | 0 | |
Capex to depreciation | -0.01 | 0 | -2 | 0 | -3.33 | |
Stock based compensation to revenue | 2.44 | 215.99 | 148.96 | 0 | 0 | |
Graham number | 1.71K | 4.24K | 1.13K | 359.57 | 68.1 | |
ROIC | -2.29 | -1.64 | 0.64 | -5.59 | -1.07 | |
Return on tangible assets | -0.71 | -1.41 | -3.5 | -2.18 | -0.81 | |
Graham Net | 291.66 | 501.42 | -359.75 | 28.81 | 10.74 | |
Working capital | 5.46M | 4.42M | -7.19M | 9.88M | 11.72M | |
Tangible asset value | 5.29M | 4.46M | -16.6M | 7.37M | 12.48M | |
Net current asset value | 4.87M | 4.19M | -18.73M | 7.23M | 11.45M | |
Invested capital | 0 | 0.04 | -0.09 | 0.03 | 0.03 | |
Average receivables | 364.79K | 189.53K | 40.03K | 104.5K | 794K | |
Average payables | 853.81K | 828.49K | 2.19M | 2.54M | 1.67M | |
Average inventory | 0 | 0 | -1.11M | -1.19M | -794K | |
Days sales outstanding | 502.57 | 499.44 | 1.59K | 0 | 0 | |
Days payables outstanding | 0 | 0 | 8.89K | 3.3K | 4K | |
Days of inventory on hand | 0 | 0 | -5.57K | -325.89 | -3.14K | |
Receivables turnover | 0.73 | 0.73 | 0.23 | 0 | 0 | |
Payables turnover | 0 | 0 | 0.04 | 0.11 | 0.09 | |
Inventory turnover | 0 | 0 | -0.07 | -1.12 | -0.12 | |
ROE | -0.81 | -1.63 | 0.64 | -3.7 | -1.03 | |
Capex per share | -0.11 | 0 | -0.11 | 0 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.06 | 0 | 0 | |
Net income per share | -3.66 | -3.05 | -0.5 | -0.53 | -0.49 | |
Operating cash flow per share | -3.12 | -3.76 | -0.82 | -0.34 | -0.36 | |
Free cash flow per share | -3.12 | -3.77 | -0.82 | -0.34 | -0.36 | |
Cash per share | 14.36 | 14.07 | 3.08 | 2.56 | 2.08 | |
Book value per share | 12.76 | 14.18 | 3.19 | 2.46 | 1.92 | |
Tangible book value per share | 12.76 | 14.18 | 3.19 | 2.46 | 1.92 | |
Share holders equity per share | 12.76 | 14.18 | 3.19 | 2.46 | 1.92 | |
Interest debt per share | 0.71 | 0.46 | 0.11 | 0.11 | 0.07 | |
Market cap | 4.87M | 4.58M | 15.19M | 10.91M | 4.27M | |
Enterprise value | -8.42M | -7.4M | 2.18M | -4.82M | -10.54M | |
P/E ratio | -0.34 | -0.43 | -1.77 | -0.8 | -0.3 | |
Price to sales ratio | 0 | 0 | 60.76 | 0 | 0 | |
POCF ratio | -1.6 | -1.38 | -4.31 | -4.96 | -1.61 | |
PFCF ratio | -1.6 | -1.38 | -4.31 | -4.95 | -1.61 | |
P/B Ratio | 0.39 | 0.37 | 1.11 | 0.69 | 0.3 | |
PTB ratio | 0.39 | 0.37 | 1.11 | 0.69 | 0.3 | |
EV to sales | 0 | 0 | 8.74 | 0 | 0 | |
Enterprise value over EBITDA | 2.13 | 1.98 | -0.93 | 1.42 | 2.79 | |
EV to operating cash flow | 2.77 | 2.24 | -0.62 | 2.19 | 3.96 | |
EV to free cash flow | 2.77 | 2.23 | -0.62 | 2.19 | 3.96 | |
Earnings yield | -0.73 | -0.59 | -0.14 | -0.31 | -0.84 | |
Free cash flow yield | -0.62 | -0.72 | -0.23 | -0.2 | -0.62 | |
Debt to equity | 0.06 | 0.03 | 0.02 | 0.04 | 0.04 | |
Debt to assets | 0.04 | 0.03 | 0.02 | 0.04 | 0.03 | |
Net debt to EBITDA | 3.36 | 3.2 | 5.56 | 4.64 | 3.92 | |
Current ratio | 4.31 | 4.89 | 10.88 | 7.46 | 6.14 | |
Interest coverage | -1.1K | -1.28K | -13.38 | -1.2K | 472.25 | |
Income quality | 0.76 | 0.89 | 1.51 | 0.65 | 0.74 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 6.15 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 4.96 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -5 | 0 | -2 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0.37 | 0 | 0 | |
Graham number | 32.41 | 31.17 | 5.98 | 5.41 | 4.6 | |
ROIC | -0.29 | -0.21 | -0.16 | -0.23 | -0.25 | |
Return on tangible assets | -0.22 | -0.17 | -0.14 | -0.19 | -0.21 | |
Graham Net | 10.43 | 10.74 | 2.78 | 2.17 | 1.68 | |
Working capital | 11.65M | 11.72M | 12.99M | 15.08M | 13.62M | |
Tangible asset value | 12.43M | 12.48M | 13.75M | 15.8M | 14.08M | |
Net current asset value | 11.32M | 11.45M | 12.79M | 14.92M | 13.28M | |
Invested capital | 0.06 | 0.03 | 0.02 | 0.04 | 0.04 | |
Average receivables | 20K | 729K | 883K | 181.5K | 85K | |
Average payables | 2.01M | 2.02M | 1.3M | 1.04M | 1.3M | |
Average inventory | -10K | -719K | -758K | -56.5K | -85K | |
Days sales outstanding | 0 | 0 | 118.08 | 0 | 0 | |
Days payables outstanding | 4.32K | 6.33K | 2.7K | 4.3K | 117.63K | |
Days of inventory on hand | 0 | -4.98K | -270 | -116.67 | -12.15K | |
Receivables turnover | 0 | 0 | 0.76 | 0 | 0 | |
Payables turnover | 0.02 | 0.01 | 0.03 | 0.02 | 0 | |
Inventory turnover | 0 | -0.02 | -0.33 | -0.77 | -0.01 | |
ROE | -0.29 | -0.21 | -0.16 | -0.21 | -0.26 | |
Capex per share | 0 | -0.01 | 0 | 0 | 0 |
PALI Frequently Asked Questions
What is Palisade Bio, Inc. stock symbol ?
Palisade Bio, Inc. is a US stock , located in Carlsbad of Ca and trading under the symbol PALI
Is Palisade Bio, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $1.5. The lowest prediction is $1.5 and the highest is $1.5
What is PALI stock prediction ?
What is Palisade Bio, Inc. stock quote today ?
Palisade Bio, Inc. stock price is $0.3991 today.
Is Palisade Bio, Inc. stock public?
Yes, Palisade Bio, Inc. is a publicly traded company.